Final Results of the Prospective ADVATE^® Immune Tolerance Induction Registry (PAIR) Study with Plasma- and Albumin-Free Recombinant Factor VIII

References

• Kreuz W, Ettingshausen CE, Zyschka A, et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Hemost. 2002;28(3):285–290. doi:10.1055/s-2002-32664
   Web of Science ®Google Scholar
• Gouw SC, van den Berg HM, Fischer K, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013;121(20):4046–4055. doi:10.1182/blood-2012-09-457036
   PubMed Web of Science ®Google Scholar
• Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9(4):418–435. doi:10.1046/j.1365-2516.2003.00780.x
   PubMed Web of Science ®Google Scholar
• Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia. 1998;4(4):558–563. doi:10.1046/j.1365-2516.1998.440558.x
   PubMed Web of Science ®Google Scholar
• Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia. 1999;5(3):145–154. doi:10.1046/j.1365-2516.1999.00300.x
   PubMed Web of Science ®Google Scholar
• Lorenzo JI, López A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol. 2001;113(3):600–603. doi:10.1046/j.1365-2141.2001.02828.x
   PubMed Web of Science ®Google Scholar
• Astermark J. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia. Haemophilia. 2006;12(s3):52–60. doi:10.1111/j.1365-2516.2006.01261.x
   Web of Science ®Google Scholar
• Astermark J, Altisent C, Batorova A, et al. Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia. 2010;16(5):747–766. doi:10.1111/j.1365-2516.2010.02231.x
   PubMed Web of Science ®Google Scholar
• Scalone L, Mantovani LG, Mannucci PM, Gringeri A; The COCIS Study Investigators. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia. 2006;12(2):154–162. doi:10.1111/j.1365-2516.2006.01204.x
   PubMed Web of Science ®Google Scholar
• Morfini M, Haya S, Tagariello G, et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia. 2007;13(5):606–612. doi:10.1111/j.1365-2516.2007.01518.x
   PubMed Web of Science ®Google Scholar
• Valentino LA, Kempton CL, Kruse-Jarres R, et al. US guidelines for immune tolerance induction in patients with haemophilia A and inhibitors. Haemophilia. 2015;21(5):559–567. doi:10.1111/hae.12730
   PubMed Web of Science ®Google Scholar
• Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158. doi:10.1111/hae.14046
   PubMed Web of Science ®Google Scholar
• DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia. 2007;13(s1):1–22. doi:10.1111/j.1365-2516.2007.01497.x
   Web of Science ®Google Scholar
• Hay CRM, DiMichele DM; International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012;119(6):1335–1344. doi:10.1182/blood-2011-08-369132
   PubMed Web of Science ®Google Scholar
• Nakar C, Manco-Johnson MJ, Lail A, et al. Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres. Haemophilia. 2015;21(3):365–373. doi:10.1111/hae.12608
   Web of Science ®Google Scholar
• DiMichele DM, Kroner BL; The North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost. 2002;87(1):52–57. doi:10.1055/s-0037-1612943
   PubMed Web of Science ®Google Scholar
• Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg B, Nilsson IM. Tolerance induction using the Malmö treatment model 1982–1995. Haemophilia. 1999;5(1):32–39. doi:10.1046/j.1365-2516.1999.00195.x
   Web of Science ®Google Scholar
• Lenk H; ITT Study Group. The German registry of immune tolerance treatment in hemophilia—1999 update. Haematologica. 2000;85(10 Suppl):45–47.
   PubMedGoogle Scholar
• Mariani G, Kroner B. International immune tolerance registry, 1997 update. Vox Sang. 1999;77(Suppl 1):25–27. doi:10.1159/000056710
   Web of Science ®Google Scholar
• Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood. 1995;86(3):983–988. doi:10.1182/blood.V86.3.983.983
   Web of Science ®Google Scholar
• Oldenburg J, Schwaab R, Brackmann HH. Induction of immune tolerance in haemophilia A inhibitor patients by the ‘Bonn Protocol’: predictive parameter for therapy duration and outcome. Vox Sang. 1999;77(Suppl 1):49–54. doi:10.1159/000056717
   PubMed Web of Science ®Google Scholar
• Auerswald G, Thompson AA, Recht M, et al. Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A. Thromb Haemost. 2012;107(6):1072–1082. doi:10.1160/TH11-09-0642
   PubMed Web of Science ®Google Scholar
• Valentino LA, Recht M, Dipaola J, et al. Experience with a third generation recombinant factor VIII concentrate (Advate®) for immune tolerance induction in patients with haemophilia A. Haemophilia. 2009;15(3):718–726. doi:10.1111/j.1365-2516.2008.01960.x
   PubMed Web of Science ®Google Scholar
• Rocino A, de Biasi R. Successful immune tolerance treatment with monoclonal or recombinant factor VIII concentrates in high responding inhibitor patients. Vox Sang. 1999;77(Suppl 1):65–69. doi:10.1159/000056720
   Web of Science ®Google Scholar
• Scheibel E, Ingerslev J, Dalsgaard-Nielsen J, Stenbjerg S, Knudsen JB. Continuous high-dose factor VIII for the induction of immune tolerance in haemophilia A patients with high responder state: a description of eleven patients treated. Thromb Haemost. 1987;58(4):1049–1052. doi:10.1055/s-0038-1646054
   Web of Science ®Google Scholar
• Dimichele DM, Hay CR. The international immune tolerance study: a multicenter prospective randomized trial in progress. J Thromb Haemost. 2006;4(10):2271–2273. doi:10.1111/j.1538-7836.2006.02127.x
   Web of Science ®Google Scholar
• Yoshioka A, Ishii E, Ueno T, et al. The international immune tolerance induction study and its follow-up study on Japanese hemophilia A patients with inhibitors. Int J Hematol. 2015;101(4):362–368. doi:10.1007/s12185-015-1734-z
   Web of Science ®Google Scholar
• Advate [antihemophilic factor (recombinant)] lyophilized powder for reconstitution, for intravenous injection [prescribing information]. Lexington, MA: Baxalta US Inc.; 2018. Available from: https://www.shirecontent.com/PI/PDFs/ADVATE_USA_ENG.pdf. Accessed November 15, 2021.
   Google Scholar
• Iorio A, Marcucci M, Cheng J, et al. Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM. Haemophilia. 2014;20(6):777–783. doi:10.1111/hae.12480
   Web of Science ®Google Scholar
• Romanov V, Marcucci M, Cheng J, Thabane L, Iorio A. Evaluation of safety and effectiveness of factor VIII treatment in haemophilia A patients with low titre inhibitors or a personal history of inhibitor. Patient data meta-analysis of rAFH-PFM Post-Authorization Safety Studies. Thromb Haemost. 2015;114(1):56–64. doi:10.1160/TH14-10-0882
   Web of Science ®Google Scholar
• Wall C, Moore J, Thachil J. Catheter-related thrombosis: a practical approach. J Intensive Care Soc. 2016;17(2):160–167. doi:10.1177/1751143715618683
   PubMedGoogle Scholar
• Spotts G, Abbuehl BE, Luu HD, et al. Safety and efficacy profile of rAHF-PFM for immune tolerance induction as assessed in 3 clinical trials (PUP ITI, PRE-PAIR, and PAIR). Blood. 2010;116(21):3670. doi:10.1182/blood.V116.21.3670.3670
   Web of Science ®Google Scholar
• Antun A, Monahan PE, Manco-Johnson MJ, et al. Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort study. J Thromb Haemost. 2015;13(11):1980–1988. doi:10.1111/jth.13143
   PubMed Web of Science ®Google Scholar
• Coppola A, Margaglione M, Santagostino E, et al. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost. 2009;7(11):1809–1815. doi:10.1111/j.1538-7836.2009.03615.x
   PubMed Web of Science ®Google Scholar
• Mariani G, Kroner B; Immune Tolerance Study G. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologica. 2001;86(11):1186–1193.
   PubMed Web of Science ®Google Scholar